Adaptimmune stock plunges after announcing Nasdaq delisting plans
IRVINE, Calif. - Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), a $171 million market cap biotechnology company whose stock has gained 4% in the past week, will present topline results from its Phase 2 BESTOW trial at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting in Houston, according to a press release issued by the company today.
The presentation will focus on tegoprubart, Eledon’s investigational drug for the prevention of rejection in kidney transplantation. Dr. Andrew Adams, Professor of Surgery and Chief Division of Transplantation at the University of Minnesota, will deliver the oral presentation on November 6 at 5:30 p.m. CT during the Late-Breaking Research Orals session. According to InvestingPro data, analysts maintain a strong buy consensus on ELDN with price targets ranging from $8 to $12.
Tegoprubart is an anti-CD40L antibody that targets the CD40 Ligand, a biological target involved in immune cell activation and function. The company is developing the drug as a non-lymphocyte depleting immunomodulatory treatment.
Following the conference presentation, Eledon will hold a conference call and webcast on November 7 at 8:00 a.m. ET to discuss the trial results.
Eledon Pharmaceuticals is a clinical-stage biotechnology company based in Irvine, California. In addition to kidney transplantation, the company is studying tegoprubart for potential applications in xenotransplantation and amyotrophic lateral sclerosis (ALS).
In other recent news, Eledon Pharmaceuticals, Inc. is set to present updated clinical data from its ongoing Phase 1b study of tegoprubart at the World Transplant Congress in San Francisco. The study focuses on the prevention of kidney transplant rejection and includes results from approximately 30 kidney transplant recipients. Dr. John Gill from the University of British Columbia will deliver an oral presentation on August 6, 2025, detailing these findings. Additionally, Eledon Pharmaceuticals plans to host a conference call and webcast on the same day to discuss the new clinical data further. This conference call will take place at 4:30 p.m. ET, providing an opportunity for stakeholders to gain deeper insights into the study’s outcomes. These presentations and discussions represent significant developments for Eledon Pharmaceuticals in the field of kidney transplantation research.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.